Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H25N2 |
| Molecular Weight | 233.3724 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CC[N+]1(CC)CCCN(CC1)C2=CC=CC=C2
InChI
InChIKey=DAPFMGRCDFSUSN-UHFFFAOYSA-N
InChI=1S/C15H25N2/c1-3-17(4-2)13-8-11-16(12-14-17)15-9-6-5-7-10-15/h5-7,9-10H,3-4,8,11-14H2,1-2H3/q+1
| Molecular Formula | C15H25N2 |
| Molecular Weight | 233.3724 |
| Charge | 1 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:47 UTC 2023
by
admin
on
Sat Dec 16 11:18:47 UTC 2023
|
| Record UNII |
7N7MB1SWWJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1609534-88-4
Created by
admin on Sat Dec 16 11:18:47 UTC 2023 , Edited by admin on Sat Dec 16 11:18:47 UTC 2023
|
PRIMARY | |||
|
7N7MB1SWWJ
Created by
admin on Sat Dec 16 11:18:47 UTC 2023 , Edited by admin on Sat Dec 16 11:18:47 UTC 2023
|
PRIMARY | |||
|
58063720
Created by
admin on Sat Dec 16 11:18:47 UTC 2023 , Edited by admin on Sat Dec 16 11:18:47 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Asmacure; Developer: Odan Laboratories; Class: Antiasthmatic, Small molecule; Mechanism of Action: Muscarinic receptor modulator, Nicotinic receptor agonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase II for Allergic asthma, Asthma, Chronic obstructive pulmonary disease; Most Recent Events: 19 Aug 2015 Odan Laboratories acquires Asmacure Ltee, 10 Aug 2015 Phase-II development is ongoing for ASM 024 as a dry powder for inhalation for Asthma and chronic obstructive pulmonary disease, 08 Feb 2015 Asmacure terminates a phase I/II trial in Asthma in Canada (Inhalation, powder) (NCT01793298)
|
||
|
ACTIVE MOIETY |
ASM-024, a homopiperazinium compound, derived from the structural modification of diphenylmethylpiperazinium (DMPP), has been developed to offer an alternative mechanism of action that could provide symptomatic control through combined anti-inflammatory and bronchodilator properties in a single entity. A dose-dependent inhibition of cellular inflammation in bronchoalveolar lavage fluid was observed in ovalbumin-sensitized mice, subsequently treated for 3 days by nose-only exposure with aerosolized ASM-024 at doses up to 3.8 mg/kg (ED50=0.03 mg/kg). The methacholine ED250 values indicated that airway hyperresponsivenness (AHR) to methacholine decreased following ASM-024 administration by inhalation at a dose of 1.5 mg/kg, with a value of 0.145+/-0.032 mg/kg for ASM 024-treated group as compared to 0.088+/-0.023 mg/kg for untreated mice.
|
||
|
ACTIVE MOIETY |
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ASM-024 Administered by Dry Powder Inhalation to Healthy Subjects and Subjects With Stable Moderate Asthma
Purpose: The purpose of this study is to evaluate the safety and tolerability of the dry powder formulation of ASM-024 following single and multiple administration by inhalation of ascending doses in healthy subjects and subjects with stable moderate asthma.
|
